Dermatologists are likely to periodically encounter candidiasis in clinical practice, especially given the increased risk with the use of new broad-spectrum IL-17 blocking psoriasis agents such as bimekizumab. Oral candidiasis may be white or red, classically presenting as cottage-cheese consistency plaques associated with symptoms of a burning mouth and dysgeusia. Standard first- and second-line antifungal medications can easily and safely be prescribed by dermatologists. In this article, we summarize clinical presentations and treatment algorithms for oral candidiasis relevant to the dermatologist. We also present indications and criteria for infectious disease referral or hospitalization. J Drugs Dermatol. 2024;23(12):e186-e190. doi:10.36849/JDD.8481e.
No clinical trial protocols linked to this paper
Clinical trials are automatically linked when NCT numbers are found in the paper's title or abstract.PICO Elements
No PICO elements extracted yet. Click "Extract PICO" to analyze this paper.
Paper Details
MeSH Terms
Associated Data
No associated datasets or code repositories found for this paper.
Related Papers
Related paper suggestions will be available in future updates.